Inotuzumab ozogamicin is an effective salvage therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with high-risk molecular features, including TP53 loss Meeting Abstract
| Authors: | Yang, X.; King, A. C.; Kabel, C. C.; Forlenza, C. J.; Park, J. H.; Geyer, M. B. |
| Abstract Title: | Inotuzumab ozogamicin is an effective salvage therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with high-risk molecular features, including TP53 loss |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577164601181 |
| DOI: | 10.1182/blood-2019-125165 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3888 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
